- High dose of the patented oral probiotic strain Streptococcus salivarius K12
- Fights bacteria that cause bad breath
- Promotes a healthy oral microbiome, which acts as a first line of defence against infections
- Naturally sweetened with a fresh minty taste
- Suggested Use
Halitosis, or bad breath, can be caused by a number of factors. It may indicate a local exposure to malodorous foods, an infection or a deeper more systemic concern. The odour itself relates to volatile compounds that have a high sulfur content and are produced by gram negative bacteria on the tongue, or between and around teeth. Halitosis can be transient (such as from sulfuric foods, tobacco products, or dry mouth) or it can persist. Persistent halitosis can indicate a systemic or local infection, post nasal drip, GERD, kidney disease, or even liver failure, though systemic diseases only account for 10% of these cases. Cleaning the tongue, by brushing or with mouthwashes, can remove some of the offensive compounds (food remnants, dead cells etc.) that the bacteria feed on, clear away bacteria themselves, or mask the odour for a period of time. But treatment of the underlying cause is ultimately best practice. One of the most effective treatments is to ensure that the oral microbiota is healthy. Breath Biotics with BLIS K12 contains a patented strain of the probiotic Streptococcus salivarius K12, to ensure a healthy oral microflora. By increasing the good bacteria present in the mouth you can reduce bacteria that cause bad breath, and strengthen your first line of defense against infections.
Oral Health and Overall Health
The oral cavity is the first point of entry for many pathogens, there can be systemic implications of oral infections. Poor oral health has been implicated as a risk factor in a number of chronic illnesses from cognitive decline to cardiovascular concerns. The moist environment makes the tongue ideal for anaerobic bacteria to grow. Poor oral health can lead to the growth of bacteria such as Streptococcus pyogenes which are a primary cause of sore throat. More serious pathogens such as Streptococcus viridans have been linked to heart conditions such as endocarditis and valvular dysfunction. This highlights the importance of oral healthcare.
The Oral Microbiome
Much of the research over the last decade regarding the systemic benefits of maintaining a diverse bacterial microflora has lead to a greater awareness of the gut bacteria. However, beneficial bacteria exist outside of the gut, on the skin, nose and oropharynx. Bacteria in the mouth and throat initiate digestion and drug metabolism, act as barriers against infection, and communicate with the immune system. These bacteria are also integral to dental structure and health. A number of strains have been identified as oral probiotics and have been researched in various forms such as tablets, sprays, and mouthwashes for a number of oral health concerns arising from dysbiosis.
What is halitosis?
Halitosis, or bad breath, can be caused by a number of factors. It may indicate a local exposure to malodorous foods, an infection or a deeper, more systemic concern. The odour itself usually relates to volatile compounds that have a high sulfur content and are produced when gram negative bacteria on the tongue or enzymes in the saliva digest sulfur containing foods. Halitosis can be transient (such as from sulfuric foods, tobacco products, or dry mouth) or it can persist. Persistent halitosis can indicate a systemic or local infection, post nasal drip, GERD, kidney disease, or even liver failure, though systemic diseases only account for 10% of these cases. Cleaning the tongue, by brushing or with mouthwashes, can remove some of the offensive compounds (food remnants, dead cells etc.) that the bacteria feed on, clear away bacteria themselves, or mask the odour for a period of time.
Halitosis and Strep. Salivarius K12
Oral treatment of halitosis with S. salivarius was shown to reduce the production of volatile sulphur compounds that cause bad breath.
Blis K12 and S.pyogenes infection
780 Children in New Zealand were monitored for 10 months to measure the incidence of group A streptococci infection. It was found that those positive for Streptococcus salivarius were significantly less likely to acquire infections. Another study in Brazil found that children who did not experience frequent sore throats had significantly higher production of bacteriocin-like inhibitory substance (BLIS) produced by S. Salivarius colonizing the mouth and pharynx.
Blis K12 upper respiratory tract health
Post antibiotic repopulation with S. salivarius showed reduction in recurrent episodes of otitis media in children.
Most probiotic products are targeted to improving gut health, while oral strains have only recently begun to gain more traction. Mouthwashes containing zinc or chlorine dioxide, and dental treatment can provide some support; however, they are not addressing oral dysbiosis, and may even be contributing to it by killing off oral bacteria without replacing it with beneficial strains.
Burton, J.P., et al., A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol, 2006. 100(4): p. 754-64.
Burton, J. P., S. Cowley, et al. (2011). “Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: A randomized, placebo-controlled, double-blind study.” Food Chem Toxicol 49(9): 2356-2364.
Chilcott, C., et al., Elevated levels of interferon gamma in human saliva following ingestion of Streptococcus salivarius K12, in Joint New Zealand an Australian Microbiological Societies Annual Meeting. 2005: Dunedin.
Dierksen, K. P., C. J. Moore, et al. (2007). “The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue.” FEMS Microbiol Ecol 59(3): 584-591.
Dierksen, K. P., and J. Tagg. 2000. The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. p. 81-85. In D. R. Martin and T. J. (ed.), Streptococci and streptococcal diseases entering the new millennium. Securacopy, Auckland. Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. 2014 Feb 13;6:15-20. doi: 10.2147/DHPS.S59665. eCollection 2014.
Fantinato V, Jeorge AOA, Shimizu MT. 1999. Production of bacteriocin-like inhibitory substances (BLIS) by Streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Rev. Microbiol. 30:332-34.
Kreth, J., Giacaman, R. A., Raghavan, R. and Merritt, J. (2016), The Road Less Traveled – Defining molecular commensalism with Streptococcus sanguinis. Mol oral Microbiol. Accepted Author Manuscript. doi:10.1111/omi.12170 Marchetti E, Tecco S, Santonico M, Vernile C, Ciciarelli D, Tarantino E, Marzo G, Pennazza G. Multi-Sensor Approach for the Monitoring of Halitosis Treatment via Lactobacillus brevis (CD2)-Containing Lozenges–A Randomized, Double-Blind Placebo-Controlled Clinical Trial. Sensors (Basel). 2015 Aug 10;15(8):19583-96. doi: 10.3390/s150819583.
Power DA, Burton JP, Chilcott CN, PJ Dawes and Tagg JR (2008) Preliminary Investigations of the Colonisation of Upper Respiratory Tract Tissues of Infants Using a Paediatric Formulation of the Oral Probiotic Streptococcus salivarius K12. European Journal of Clinical Microbiology & Infectious Diseases 27: 1261 -3.
Walls, T., D. Power, and J. Tagg, Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol, 2003. 52(Pt 9): p. 829-33.
Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012 Dec;7(12):1355-71. doi: 10.2217/fmb.12.113.
Wescombe, P. A., Upton, M., Dierksen, K. P., Ragland, N. L., Sivabalan, S., Wirawan, R. E., Inglis, M. A., Moore, C. J., Walker, G. V., Chilcott, C. N., Jenkinson, H. F., Tagg, J. R. (2006). Production of the Lantibiotic Salivaricin A and Its Variants by Oral Streptococci and Use of a Specific
Induction Assay To Detect Their Presence in Human Saliva. Appl. Environ. Microbiol. 72: 1459- 1466
Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012 Dec;7(12):1355-71. doi: 10.2217/fmb.12.113.
Abstract: Considerable human illness can be linked to the development of oral microbiota disequilibria. The predominant oral cavity commensal, Streptococcus salivarius has emerged as an important source of safe and efficacious probiotics, capable of fostering more balanced, health-associated oral microbiota. Strain K12, the prototype S. salivarius probiotic, originally introduced to counter Streptococcus pyogenes infections, now has an expanded repertoire of health-promoting applications. K12 and several more recently proposed S. salivarius probiotics are now being applied to control diverse bacterial consortia infections including otitis media, halitosis and dental caries. Other potential applications include upregulation of immunological defenses against respiratory viral infections and treatment of oral candidosis. An overview of the key steps required for probiotic development is also presented.
Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. 2014 Feb 13;6:15-20. doi: 10.2147/DHPS.S59665. eCollection 2014.
BACKGROUND: Streptococcus salivarius K12 is an oral probiotic strain releasing two lantibiotics (salivaricin A2 and salivaricin B) that antagonize the growth of S. pyogenes, the most important bacterial cause of pharyngeal infections in humans also affected by episodes of acute otitis media. S. salivarius K12 successfully colonizes the oral cavity, and is endowed with an excellent safety profile. We tested its preventive role in reducing the incidence of both streptococcal and viral pharyngitis and/or tonsillitis in children.
MATERIALS AND METHODS: We enrolled 61 children with a diagnosis of recurrent oral streptococcal disorders. Thirty-one of them were enrolled to be treated daily for 90 days with a slow-release tablet for oral use, containing no less than 1 billion colony-forming units/tablet of S. salivarius K12 (Bactoblis®), and the remaining 30 served as the untreated control group. During treatment, they were all examined for streptococcal infection. Twenty children (ten per group) were also assessed in terms of viral infection. Secondary end points in both groups were the number of days under antibiotic and antipyretic therapy and the number of days off school (children) and off work (parents).
RESULTS: The 30 children who completed the 90-day trial with Bactoblis® showed a significant reduction in their episodes of streptococcal pharyngeal infection (>90%), as calculated by comparing the infection rates of the previous year. No difference was observed in the control group. The treated group showed a significant decrease in the incidence (80%) of oral viral infections. Again, there was no difference in the control group. With regard to secondary end points, the number of days under antibiotic treatment of the treated and control groups were 30 and 900 respectively, days under antipyretic treatment 16 and 228, days of absence from school 16 and 228, and days of absence from work 16 and 228. The product was well tolerated by the subjects, with no side effects, and only one individual reported bad product palatability and dropped out.
CONCLUSION: Prophylactic administration of S. salivarius K12 to children with a history of recurrent oral streptococcal disease resulted in a considerable reduction of episodes of both streptococcal and viral infections and reduced the number of days under antibiotic and/or antipyretic therapy and days of absence from school or work
Penala S, Kalakonda B, Pathakota KR, Jayakumar A, Koppolu P, Lakshmi BV, Pandey R, Mishra A. Efficacy of local use of probiotics as an adjunct to scaling and root planing in chronic periodontitis and halitosis: A randomized controlled trial.J Res Pharm Pract. 2016 Apr-Jun;5(2):86-93. doi: 10.4103/2279-042X.179568.
Periodontitis is known to have multifactorial etiology, involving interplay between environmental, host and microbial factors. The current treatment approaches are aimed at reducing the pathogenic microorganisms. Administration of beneficial bacteria (probiotics) has emerged as a promising concept in the prevention and treatment of periodontitis. Thus, the aim of the present study is to evaluate the efficacy of the local use of probiotics as an adjunct to scaling and root planing (SRP) in the treatment of patients with chronic periodontitis and halitosis.
This is a randomized, placebo-controlled, double-blinded trial involving 32 systemically healthy chronic periodontitis patients. After SRP, the subjects were randomly assigned into the test and control groups. Test group (SRP probiotics) received subgingival delivery ofprobiotics and probiotic mouthwash, and control group (SRP placebo) received subgingival delivery of placebo and placebo mouthwash for 15 days. Plaque index (PI), modified gingival index (MGI), and bleeding index (BI) were assessed at baseline, 1 and 3 months thereafter, whereas probing depth (PD) and clinical attachment level were assessed at baseline and after 3 months. Microbial assessment using N-benzoyl-DL-arginine-naphthylamide (BANA) and halitosis assessment using organoleptic scores (ORG) was done at baseline, 1 and 3 months.
All the clinical and microbiological parameters were significantly reduced in both groups at the end of the study. Inter-group comparison of PD reduction (PDR) and clinical attachment gain (CAG) revealed no statistical significance except for PDR in moderate pockets for the test group. Test group has shown statistically significant improvement in PI, MGI, and BI at 3 months compared to control group. Inter-group comparison revealed a significant reduction in BANA in test group at 1 month. ORG were significantly reduced in test group when compared to control group.
Within the limitations of the study, the present investigation showed that the adjunctive use of probiotics offers clinical benefit in terms of pocket depth reduction in moderate pockets and reduced oral malodor parameters.
Burton, J. P., S. Cowley, et al. (2011). “Evaluation of safety and human tolerance of the oral
probiotic Streptococcus salivarius K12: A randomized, placebo-controlled, double-blind study.” Food Chem Toxicol 49(9): 2356-2364.
Streptococcus salivarius is naturally a predominant member of the human oropharynx and the commercial probiotic strain K12 has been consumed for more than a decade. The present study examines the health responses of human volunteers to oral ingestion of high doses of S.salivarius K12. A randomized group of 53 subjects received a dose of 1 × 10(10)cfu S. salivarius K12 (N=25) or placebo (N=28) for 28 days, followed by a 28-day wash out period. Blood, urine and saliva samples were collected at baseline and following treatment and analyzed, while the oral and gastrointestinal tolerance of the subjects to the dosing regimen was determined by use of questionnaires. Adverse events (AE)s were recorded for both groups. No statistically significant differences between the probiotic and placebo treated groups were detected in either the blood clinical chemistry or hematology results (P>0.05). The questionnaire responses of the subjects indicated that both treatments were well tolerated. The frequency and intensity of AEs was similar in the two groups. This data demonstrates that the daily ingestion of S. salivarius K12 over a 28-day period does not adversely affect the human host and supports the safety of its oral delivery in a food-based carrier.
Directions (Adults): For general oral health, take one to two lozenges per day. For prevention of sore throat due to infection in adults, take one to two lozenges per day for 90 days. To reduce halitosis, following use of an antimicrobial mouthwash (such as chlorhexidine or cetylpyridinium chloride), take up to four lozenges a day for a minimum of 14 days. This lozenge is not to be chewed or directly swallowed; it must be slowly dissolved in the mouth. If you are on antibiotics, take at least 24 hours following last dose.
Directions (Children): For prevention of sore throat due to infection in children under 12 years of age, take one lozenge per day for 90 days; children 12 years and older, take one to two lozenges per day for 90 days. To reduce halitosis, following use of an antimicrobial mouthwash (such as chlorhexidine or cetylpyridinium chloride), children older than nine years, take up to four lozenges a day for a minimum of 14 days; children nine years and younger, take one lozenge a day for a minimum of seven days. This lozenge is not to be chewed or directly swallowed; it must be slowly dissolved in the mouth. Children under six years of age should be supervised (to not swallow). If you are on antibiotics, take at least 24 hours following last dose.
Suggested Usage: Breath Biotics is Streptococcus salivarius K12, an oral probiotic which helps reduce halitosis (bad breath), following antimicrobial rinsing and promotes oral health. Breath Biotics can also help reduce the incidence of sore throat caused by pathogenic Streptococcus pyogenes.
- Bad breath
- Oral health
- Sore throat
Disclaimer: The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Cautions: Consult a health care practitioner prior to use if you have fever, vomiting, bloody diarrhea, or severe abdominal pain. Do not use if you have an immune compromised condition (e.g. AIDS, lymphoma, undergoing long-term corticosteroid treatment), are taking aminoglycoside antibiotics (e.g. kanamycin, streptomycin), or have a dairy allergy. If symptoms of ear, nose or throat infections (e.g. fever, sore throat) occur, or if symptoms of digestive upset (e.g. diarrhea) occur, worsen or persist beyond three days, discontinue use and consult a health care practitioner. Do not use if you have a corn allergy.
Serving Size: 1 Lozenge
Servings Per Container: 60
Per Serving BLIS K12™* (Streptococcus salivarius K12) 1 billion CFU †Colony-forming units
*BLIS™ and BLIS K12™: is a registered trademark of Blis Technologies Limited and the subject of USA patent no. 6773912
Non-Medicinal Ingredients: Isomalt, sodium stearyl fumarate, maltodextrin, monk fruit extract, starch, hyprolose, trehalose, lacitol, natural flavour (wintergreen, peppermint).